JP Morgan Chase
SPRO icon

JP Morgan Chase’s Spero Therapeutics SPRO Stock Holding History

JP Morgan Chase’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$529 Sell
236
-5,137
-96% -$12.2K ﹤0.01% 7172
2025
Q4 		$12.5K Buy
5,373
+5,137
+2,177% +$11.9K ﹤0.01% 6610
2025
Q3 		$444 Hold
236
– – ﹤0.01% 7061
2025
Q2 		$684 Sell
236
-60,581
-100% -$87.1K ﹤0.01% 6664
2025
Q1 		$43.8K Sell
60,817
-807
-1% -$681 ﹤0.01% 5924
2024
Q4 		$63.5K Buy
61,624
+61,388
+26,012% +$73K ﹤0.01% 5924
2024
Q3 		$316 Hold
236
– – ﹤0.01% 6852
2024
Q2 		$307 Hold
236
– – ﹤0.01% 6734
2024
Q1 		$406 Hold
236
– – ﹤0.01% 6747
2023
Q4 		$347 Hold
236
– – ﹤0.01% 6977
2023
Q3 		$286 Hold
236
– – ﹤0.01% 6799
2023
Q2 		$342 Hold
236
– – ﹤0.01% 6577
2023
Q1 		$0 Hold
236
– – ﹤0.01% 7192
2022
Q4 		$0 Sell
236
-1,352
-85% -$2.52K ﹤0.01% 6975
2022
Q3 		$3K Buy
1,588
+313
+25% +$311 ﹤0.01% 6198
2022
Q2 		$1K Sell
1,275
-79,897
-98% -$232K ﹤0.01% 6381
2022
Q1 		$706K Sell
81,172
-16,013
-16% -$164K ﹤0.01% 4484
2021
Q4 		$1.56M Sell
97,185
-7,749
-7% -$123K ﹤0.01% 4035
2021
Q3 		$1.93M Sell
104,934
-10,922
-9% -$175K ﹤0.01% 3821
2021
Q2 		$1.62M Buy
115,856
+47,287
+69% +$661K ﹤0.01% 3943
2021
Q1 		$1.01M Sell
68,569
-5,106
-7% -$89.9K ﹤0.01% 4221
2020
Q4 		$1.43M Sell
73,675
-16,213
-18% -$253K ﹤0.01% 3722
2020
Q3 		$895K Sell
89,888
-9,887
-10% -$117K ﹤0.01% 3704
2020
Q2 		$1.35M Buy
99,775
+21,669
+28% +$243K ﹤0.01% 3339
2020
Q1 		$631K Sell
78,106
-55,172
-41% -$486K ﹤0.01% 3708
2019
Q4 		$1.28M Sell
133,278
-33,448
-20% -$361K ﹤0.01% 3678
2019
Q3 		$1.77M Buy
166,726
+2,337
+1% +$24.6K ﹤0.01% 3502
2019
Q2 		$1.83M Buy
164,389
+13,814
+9% +$166K ﹤0.01% 3449
2019
Q1 		$1.93M Sell
150,575
-35,601
-19% -$378K ﹤0.01% 3351
2018
Q4 		$1.15M Buy
186,176
+9,693
+5% +$78.5K ﹤0.01% 3657
2018
Q3 		$1.85M Buy
176,483
+37,840
+27% +$439K ﹤0.01% 3512
2018
Q2 		$2.03M Sell
138,643
-117,710
-46% -$1.51M ﹤0.01% 3400
2018
Q1 		$3.65M Buy
256,353
+255,052
+19,604% +$3.09M ﹤0.01% 2833
2017
Q4 		$15K Buy
+1,301
New +$16K ﹤0.01% 5209

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JP Morgan Chase's SPRO Position: Q1 2026 in Review

JP Morgan Chase reduced its Spero Therapeutics (SPRO) stake by 96% in Q1 2026, selling an estimated $12.2K and leaving 236 shares worth $529. The position accounts for ﹤0.01% of the portfolio, ranked #7172.

JP Morgan Chase first reported a position in SPRO in Q4 2017 and has held it in 34 quarters since. The position peaked at $3.65M in Q1 2018. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • JP Morgan Chase held 236 shares of Spero Therapeutics worth $529 as of Q1 2026.
  • JP Morgan Chase sold 5,137 Spero Therapeutics shares in Q1 2026, an estimated $12.2K.
  • Spero Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7172 holding.
  • JP Morgan Chase first reported a position in Spero Therapeutics in Q4 2017 and has held it in 34 quarters since.
  • JP Morgan Chase's Spero Therapeutics position peaked at $3.65M in Q1 2018.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.